Patents Assigned to Merck Serono SA
  • PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS
    Publication number: 20120071460
    Abstract: The present invention relates to pyrazole oxadiazoles derivatives of Formula (I), and their use for treating multiple sclerosis and other diseases, wherein R1, R2 and R3 are as defined in the description.
    Type: Application
    Filed: June 7, 2010
    Publication date: March 22, 2012
    Applicant: MERCK SERONO SA
    Inventors: Anna Quattropani, Charles Baker-Glenn, Wesley Blackaby, Chris Knight
  • Use of IL-18BP isoforms for the treatment and/or prevention of neurological inflammatory diseases
    Patent number: 8128920
    Abstract: The invention relates to the use of an IL18-BP isoform that does not bind to IL18, or of an agonist thereof, for treatment or prevention of a neurological and/or inflammatory disease. Preferred isoforms for use in the frame of the invention include IL-18BPb and IL-18BPd.
    Type: Grant
    Filed: June 2, 2006
    Date of Patent: March 6, 2012
    Assignee: Merck Serono SA
    Inventors: Yves Sagot, Yolande Chvatchko, Anne Corbaz
  • OXADIAZOLE DERIVATIVES
    Publication number: 20120035226
    Abstract: The invention relates to oxadiazole compounds of formula I. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.
    Type: Application
    Filed: March 29, 2010
    Publication date: February 9, 2012
    Applicant: MERCK SERONO SA
    Inventors: Anna Quattropani, Cyril Montagne, Wolfgang Sauer, Stefano Crosignani, Agnés Bombrun
  • 2-imino-4-(thio) oxo-5-polycyclovinylazolines for use as PI3 kinase inhibitors
    Patent number: 8106214
    Abstract: The present invention is related to 2-imino-azolinone-vinyl fused-benzene derivatives of Formula (1) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.
    Type: Grant
    Filed: July 27, 2004
    Date of Patent: January 31, 2012
    Assignee: Merck Serono SA
    Inventors: Thomas Rueckle, Jeffrey Shaw, Dennis Church, David Covini
  • OXADIAZOLE DERIVATIVES
    Publication number: 20120022109
    Abstract: The invention relates to oxadiazole compounds of formula I. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.
    Type: Application
    Filed: March 29, 2010
    Publication date: January 26, 2012
    Applicant: MERCK SERONO SA
    Inventors: Anna Quattropani, Cyril Montagne, Wolfgang Sauer, Stefano Crosignani, Agnès Bombrun
  • GENETIC SEVERITY MARKERS IN MULTIPLE SCLEROSIS
    Publication number: 20120003182
    Abstract: The present invention relates to the use of SNPs in predicting susceptibility and/or severity of Multiple Sclerosis in an individual. The SNPs are located in the introns of the glycosylation enzymes MGAT5 and XYLT1, 3? of HIF1AN, within introns of MEGF11. FGF14, PDE9A and CDH13 and within desert regions of 4q34 and 17p13.
    Type: Application
    Filed: March 25, 2010
    Publication date: January 5, 2012
    Applicant: MERCK SERONO SA
    Inventors: Hadi Abderrahim, Jérôme Wojcik, Federica Esposito, Virginie Debailleul
  • PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS
    Publication number: 20110319410
    Abstract: The present invention is related to pyrazine derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.
    Type: Application
    Filed: August 31, 2011
    Publication date: December 29, 2011
    Applicant: MERCK SERONO SA
    Inventors: PASCALE GAILLARD, Anna Quattropani, Vincent Pomel, Thomas Rueckle, Jasna Klicic, Dennis Church
  • PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS
    Publication number: 20110312960
    Abstract: The present invention is related to pyrazine derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.
    Type: Application
    Filed: August 31, 2011
    Publication date: December 22, 2011
    Applicant: MERCK SERONO SA
    Inventors: Pascale Gaillard, Anna Quattropani, Vincent Pomel, Thomas Rueckle, Jasna Klicic, Dennis Church
  • OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS
    Publication number: 20110306636
    Abstract: The present invention provides oxadiazole pyridine derivatives of Formula (I), their use as medicaments and their use for treating multiple sclerosis and other diseases.
    Type: Application
    Filed: March 2, 2010
    Publication date: December 15, 2011
    Applicant: Merck Serono SA
    Inventors: Anna Quattropani, Patrick Gerber, Jerome Dorbais
  • Use of soluble CD164 in inflammatory and/or autoimmune disorders
    Patent number: 8075894
    Abstract: The present invention relates to novel therapeutic uses of soluble proteins comprising the extracellular region of human CD164, in particular for treating inflammatory and/or autoimmune disorders.
    Type: Grant
    Filed: December 22, 2008
    Date of Patent: December 13, 2011
    Assignee: Merck Serono SA
    Inventor: Yolande Chvatchko
  • Pyrazine compounds and uses as PI3K inhibitors
    Patent number: 8071597
    Abstract: The present invention is related to pyrazine derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.
    Type: Grant
    Filed: August 25, 2006
    Date of Patent: December 6, 2011
    Assignee: Merck Serono SA
    Inventors: Pascale Gaillard, Anna Quattropani, Vincent Pomel, Thomas Rueckle, Jasna Klicic, Dennis Church
  • Use of IL-6-type cytokines for maturation of oocytes
    Patent number: 8071375
    Abstract: The use of certain IL-6-type cytokines for the in vitro maturation of mammalian oocytes is described. The in vitro matured oocytes may be used in in vitro fertilization protocols.
    Type: Grant
    Filed: November 26, 2004
    Date of Patent: December 6, 2011
    Assignee: Merck Serono SA
    Inventors: Ann M. Clark, Daniel Gustavo de Matos, Jennifer A. Jackson, Stephen S. Palmer, Cam Anh T. Tran
  • N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF
    Publication number: 20110281891
    Abstract: The present invention is related to N-hydroxyamide derivatives of Formula (I) and use thereof in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis.
    Type: Application
    Filed: July 28, 2011
    Publication date: November 17, 2011
    Applicant: MERCK SERONO SA
    Inventors: Dominique SWINNEN, Jerome GONZALEZ
  • Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors
    Patent number: 8058289
    Abstract: The present invention is related to pyridine methylene azolidinone derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.
    Type: Grant
    Filed: October 18, 2010
    Date of Patent: November 15, 2011
    Assignee: Merck Serono SA
    Inventors: Thomas Rueckle, Anna Quattropani, Vincent Pomel, Jerome Dorbais, David Covini, Alexander Bischoff
  • Pyrrolidine derivatives as prostaglandin modulators
    Patent number: 8058305
    Abstract: Substituted pyrrolidine compounds are provided, and methods of treatment and pharmaceutical composition that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteoporosis and other destructive bone disease or disorder, and other diseases and disorders associated with the prostaglandin family of compounds. In a preferred aspect, a substituted pyrrolidine compound is administered to a subject in coordination with a phosphodiesterase inhibitor compound.
    Type: Grant
    Filed: August 3, 2009
    Date of Patent: November 15, 2011
    Assignee: Merck Serono SA
    Inventors: Yihua Liao, Zhong Zhao, Gian Luca Araldi
  • 9-(piperazinylalkyl) carbazoles as bax-modulators
    Patent number: 8053436
    Abstract: The present invention is related to piperazine derivatives of carbazole of formula (I) notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such piperazine derivatives of carbazole. Said piperazine derivatives of carbazole are efficient modulators, in particular efficient inhibitors, of the Bax function and/or activation. The present invention is furthermore related to novel piperazine derivatives of carbazole as well as methods of their preparation.
    Type: Grant
    Filed: October 18, 2000
    Date of Patent: November 8, 2011
    Assignee: Merck Serono SA
    Inventors: Serge Halazy, Dennis Church, Bruno Antonsson, Agnes Bombrun, Patrick Gerber, Jean-Claude Martinou
  • Method of producing functional protein domains
    Patent number: 8048645
    Abstract: The present invention provides a method of producing functional protein domains, which are fragments of primary translational products consisting of one or more distinct protein domains encoded by specific subsets of exonic sequences. The method is based on the integration, by a single homologous recombination event, of a regulatory unit into the eukaryotic gene coding for the primary translational product at the level of the intronic genomic region immediately adjacent to the exonic sequences which code for the functional protein domain.
    Type: Grant
    Filed: August 1, 2001
    Date of Patent: November 1, 2011
    Assignee: Merck Serono SA
    Inventors: Giampiero De Luca, Luca Falciola
  • 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES
    Publication number: 20110257170
    Abstract: This invention relates to compounds of Formula (I) as Pi3k inhibitors for treating autoimmune diseases, inflammatory disorders, multiple sclerosis and other diseases like cancers.
    Type: Application
    Filed: September 30, 2009
    Publication date: October 20, 2011
    Applicant: MERCK SERONO SA
    Inventors: Vincent Pomel, Pascale Gaillard, Gwenaelle Desforges, Anna Quattropani, Cyril Montagne
  • Pharmaceutically active sulfonamide derivatives
    Patent number: 8012995
    Abstract: The present invention is related to sulfonamide derivatives of formula (I0 notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such sulfonamide derivatives. Said sulfonamide derivatives are efficient modulators of the JNK pathway, they are in particular efficient and selective inhibitors of JNK 2 and 3. The present invention is furthermore related to novel sulfonamide derivatives as well as to methods of their preparation.
    Type: Grant
    Filed: September 28, 2000
    Date of Patent: September 6, 2011
    Assignee: Merck Serono SA
    Inventors: Stephen Arkinstall, Serge Halazy, Dennis Church, Montserrat Camps, Thomas Rueckle, Jean Pierre Gotteland, Marco Biamonte
  • N-hydroxyamide derivatives and use thereof
    Patent number: 8008302
    Abstract: The present invention is related to N-hydroxyamide derivatives of Formula (I) and use thereof, in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis.
    Type: Grant
    Filed: July 25, 2005
    Date of Patent: August 30, 2011
    Assignee: Merck Serono SA
    Inventors: Dominique Swinnen, Agnes Bombrun, Jerome Gonzalez, Stefano Crosignani, Patrick Gerber, Catherine Jorand-Lebrun